$8.500
-0.205 (-2.41%)At close
XLO News
XLO Events
Xilio Therapeutics Inc Trading Halted Due to Volatility Trading Pause
Xilio Therapeutics Inc trading halted, volatility trading pause
Xilio Therapeutics Doses First Patient in XTX501 Clinical Trial
Xilio Therapeutics announced that the first patient has been dosed in its Phase 1/2 clinical trial evaluating XTX501, a PD-1/masked IL-2 bispecific antibody fusion protein, in patients with metastatic non-small cell lung cancer who have previously received anti-PD(L)-1 therapy. Xilio also plans to present a trial-in-progress poster for XTX501 at the upcoming SITC Annual Meeting, highlighting the design of the Phase 1/2 clinical trial.
Xilio Therapeutics Appoints Dr. Yariv Houvras as Chief Medical Officer
Xilio Therapeutics announced the appointment of Dr. Yariv Houvras as chief medical officer. to joining Xilio, he served as senior vice president of clinical and translational development of Tubulis
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
Xilio Therapeutics announced the appointment of Ben Harshbarger as chief legal officer. recently, he served as chief legal officer at Astria Therapeutics, Inc. until its acquisition.
Xilio Therapeutics Files $250M Mixed Securities Shelf
Xilio Therapeutics files $250M mixed securities shelf
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.